SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-21-006882
Filing Date
2021-03-26
Accepted
2021-03-26 08:00:54
Documents
57
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 1589875
2 ex10-21.htm EX-10.21 13428
3 ex23-1.htm EX-23.1 3777
4 ex31-1.htm EX-31.1 10886
5 ex31-2.htm EX-31.2 10908
6 ex32-1.htm EX-32.1 5908
7 ex32-2.htm EX-32.2 6079
  Complete submission text file 0001493152-21-006882.txt   4758554

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE FILE lixt-20201231.xml EX-101.INS 584754
9 XBRL SCHEMA FILE lixt-20201231.xsd EX-101.SCH 44285
10 XBRL CALCULATION FILE lixt-20201231_cal.xml EX-101.CAL 36070
11 XBRL DEFINITION FILE lixt-20201231_def.xml EX-101.DEF 205294
12 XBRL LABEL FILE lixt-20201231_lab.xml EX-101.LAB 332635
13 XBRL PRESENTATION FILE lixt-20201231_pre.xml EX-101.PRE 266905
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39717 | Film No.: 21774753
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences